65F93AB7-AA99-49B5-8D59-7D0DE9CA9E34
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.591
- MYC_TARGETS_V1+0.588
- ANGIOGENESIS+0.573
- E2F_TARGETS+0.570
- TNFA_SIGNALING_VIA_NFKB+0.532
- MYC_TARGETS_V2+0.525
- G2M_CHECKPOINT+0.521
- DNA_REPAIR+0.498
- INFLAMMATORY_RESPONSE+0.498
- UNFOLDED_PROTEIN_RESPONSE+0.496
Top 10 suppressed
- KRAS_SIGNALING_DN-0.478
- SPERMATOGENESIS-0.316
- PANCREAS_BETA_CELLS-0.218
- MYOGENESIS-0.140
- BILE_ACID_METABOLISM-0.105
- ESTROGEN_RESPONSE_EARLY-0.008
- HEDGEHOG_SIGNALING+0.001
- ESTROGEN_RESPONSE_LATE+0.022
- HEME_METABOLISM+0.026
- APICAL_SURFACE+0.104
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.981 |
| 2 | A678E1E5-E02D-49A1-BB2B-C91A60E6382E | — | — | 0.980 |
| 3 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.979 |
| 4 | 30D8578D-0B48-4D03-9E39-6425494ECD5C | — | — | 0.979 |
| 5 | 795FBB8C-0E74-477F-AA27-1CE97A4E90B9 | — | — | 0.976 |
| 6 | SRR934965 | — | — | 0.976 |
| 7 | 2B311620-94F3-4B53-B66A-81AC0A32453B | — | — | 0.976 |
| 8 | AA762299-102B-4E35-B4A5-A94A122EF9DB | — | — | 0.976 |
| 9 | CE7A3262-C48A-43BF-941C-9D2482B9CACD | — | — | 0.976 |
| 10 | DC01D165-E257-49D6-8B9B-37CA7DE398F6 | — | — | 0.976 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.591 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.588 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.573 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.570 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.532 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.525 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.521 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.498 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.498 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.496 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.495 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.481 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.480 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.461 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.437 | Inavolisib | — uncovered |
| HYPOXIA | 0.422 | Idelalisib | — uncovered |
| APOPTOSIS | 0.421 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.420 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.414 | Inavolisib | — uncovered |